汉森制药(002412) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥213,882,410.43, a decrease of 5.44% compared to ¥226,177,460.31 in the same period last year[7] - Net profit attributable to shareholders was ¥40,221,685.17, representing a growth of 10.52% from ¥36,393,214.40 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥38,655,881.83, an increase of 6.91% compared to ¥36,158,369.82 in the previous year[7] - The basic earnings per share for the period was ¥0.1359, up 10.49% from ¥0.1230 in the same period last year[7] - Total operating revenue decreased to ¥213,882,410.43 from ¥226,177,460.31, representing a decline of approximately 5.7% year-over-year[36] - Total operating costs reduced to ¥177,711,186.75 from ¥181,522,758.30, a decrease of about 2.2% year-over-year[36] - Net profit increased to ¥40,221,685.17 compared to ¥36,393,214.40, reflecting a growth of approximately 10.5% year-over-year[39] - Operating profit rose to ¥46,454,212.33 from ¥42,610,783.21, marking an increase of around 6.5% year-over-year[38] - The company reported a total profit of ¥46,953,055.54, compared to ¥42,520,086.64, indicating an increase of about 10.2% year-over-year[38] - Total comprehensive income reached ¥41,059,904.38, up from ¥36,393,214.40, reflecting an increase of approximately 12.3% year-over-year[39] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,835,796,379.47, reflecting a 2.08% increase from ¥1,798,360,607.85 at the end of the previous year[7] - Net assets attributable to shareholders increased by 3.01% to ¥1,404,404,218.50 from ¥1,363,344,314.12 at the end of the previous year[7] - The company's total liabilities decreased slightly to CNY 431,392,160.97 from CNY 435,016,293.73, a reduction of about 0.6%[29] - The total owner's equity increased to CNY 1,404,404,218.50, up from CNY 1,363,344,314.12, reflecting a growth of approximately 3.0%[30] - The total liabilities and owner's equity totaled CNY 1,793,078,259.69, up from CNY 1,743,590,919.39, indicating an increase of about 2.8%[35] Cash Flow - The company reported a net cash flow from operating activities of ¥12,431,872.48, a decrease of 3.49% compared to ¥12,881,994.23 in the same period last year[7] - The net cash flow from operating activities for Q1 2019 was CNY 22,554,455.32, a significant increase from CNY 8,096,970.63 in Q1 2018, representing a growth of approximately 178.5%[50] - Total cash inflow from operating activities was CNY 173,662,216.42, compared to CNY 167,965,593.26 in the previous year, indicating a year-over-year increase of about 3.9%[50] - The total cash outflow from operating activities was CNY 151,107,761.10, down from CNY 159,868,622.63 in Q1 2018, reflecting a decrease of approximately 5.5%[50] - Cash flow from investing activities showed a net outflow of CNY 5,964,233.54, slightly improved from CNY 6,073,151.70 in the same period last year[50] - Cash flow from financing activities resulted in a net outflow of CNY 2,944,728.03, compared to a net outflow of CNY 3,648,219.97 in Q1 2018, indicating a reduction in cash outflow by about 19.3%[51] - The ending balance of cash and cash equivalents was CNY 61,406,419.61, an increase from CNY 47,954,155.47 at the end of Q1 2018, representing a growth of approximately 28.1%[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,094[10] - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, held 42.13% of the shares, totaling 124,709,523 shares[10] Other Financial Metrics - The weighted average return on equity was 2.91%, slightly down from 2.94% in the previous year[7] - Research and development expenses increased to ¥8,907,093.50 from ¥7,035,597.72, indicating a rise of approximately 26.6% year-over-year[36] - Investment income increased by 11.38 million yuan, a growth of 472.12%, primarily due to increased long-term equity investment income from Hunan Sanxiang Bank Co., Ltd.[15] - Other income increased by 943,200 yuan, a growth of 256.82%, mainly due to an increase in government subsidies related to daily activities recognized during the reporting period[15] - Other comprehensive income increased by 838,200 yuan, a growth of 78.92%, mainly due to increased other comprehensive income from Hunan Sanxiang Bank Co., Ltd. recognized using the equity method[14] Compliance and Operational Updates - The company received a GMP certificate for tablets, hard capsules, and oral liquids, indicating successful compliance with pharmaceutical manufacturing standards[18] - The company’s subsidiary completed the business registration change, enhancing its operational capabilities in the real estate sector[18] Changes in Assets - Current assets rose to CNY 518,701,436.62, compared to CNY 490,941,226.93, marking an increase of about 5.7%[28] - Long-term equity investments reached CNY 547,384,046.46, up from CNY 537,573,268.55, indicating a growth of approximately 1.5%[28] - Accounts receivable rose to CNY 296,727,743.04 from CNY 251,791,513.17, indicating an increase of approximately 17.8%[32] - Inventory decreased to CNY 40,265,534.57 from CNY 46,054,500.27, a decline of about 12.6%[32] - The company reported a net profit increase in retained earnings to CNY 620,887,095.18 from CNY 580,665,410.01, reflecting a growth of approximately 6.9%[30] Tax and Payments - Tax payable increased by 3.59 million yuan, a growth of 52.18%, primarily due to unremitted corporate income tax at the end of the first quarter[14] - The company reported a decrease in tax payments, with CNY 15,590,560.24 paid in Q1 2019 compared to CNY 18,951,670.35 in Q1 2018, a reduction of approximately 17.5%[50] Product and Technology Updates - The company did not report any significant new product launches or technological advancements during this quarter[52]